180 related articles for article (PubMed ID: 28860813)
41. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
[TBL] [Abstract][Full Text] [Related]
42. High or low dose radioiodine ablation of thyroid remnants?
Creutzig H
Eur J Nucl Med; 1987; 12(10):500-2. PubMed ID: 3569338
[TBL] [Abstract][Full Text] [Related]
43. FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake.
Gaertner FC; Okamoto S; Shiga T; Ito YM; Uchiyama Y; Manabe O; Hattori N; Tamaki N
Clin Nucl Med; 2015 May; 40(5):378-83. PubMed ID: 25608175
[TBL] [Abstract][Full Text] [Related]
44. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer.
Kim YI; Im HJ; Paeng JC; Cheon GJ; Kang KW; Lee DS; Joon Park D; Park YJ; Chung JK
Ann Nucl Med; 2015 Feb; 29(2):184-9. PubMed ID: 25404419
[TBL] [Abstract][Full Text] [Related]
45. Comparison of Radioactive Iodine Activities in Terms of Short- and Long-term Results in Ablation Therapy in Patients with Low-risk Differentiated Thyroid Cancer.
Saraçoğlu S; Güven O; Babacan GB; Karyağar S; Özülker T; Ergür S; Sağlampınar Karyağar S
Mol Imaging Radionucl Ther; 2023 Jun; 32(2):112-116. PubMed ID: 37337764
[TBL] [Abstract][Full Text] [Related]
46. Differentiated thyroid cancer: radioiodine following lobectomy - a clinical feasibility study.
Hoyes KP; Owens SE; Millns MM; Allan E
Nucl Med Commun; 2004 Mar; 25(3):245-51. PubMed ID: 15094442
[TBL] [Abstract][Full Text] [Related]
47. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
48. Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?
Shinto AS; Kamaleshwaran KK; Shibu DK; Vyshak K; Antony J
World J Nucl Med; 2013 May; 12(2):61-4. PubMed ID: 25125997
[TBL] [Abstract][Full Text] [Related]
49. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.
Prpic M; Kruljac I; Kust D; Kirigin LS; Jukic T; Dabelic N; Bolanca A; Kusic Z
Endocrine; 2016 Jun; 52(3):602-8. PubMed ID: 26732041
[TBL] [Abstract][Full Text] [Related]
50. Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.
Lawal IO; Nyakale NE; Harry LM; Lengana T; Mokgoro NP; Vorster M; Sathekge MM
Nucl Med Commun; 2017 Mar; 38(3):222-227. PubMed ID: 28002173
[TBL] [Abstract][Full Text] [Related]
51. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
52. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
53. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
54. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
Durante C; Montesano T; Attard M; Torlontano M; Monzani F; Costante G; Meringolo D; Ferdeghini M; Tumino S; Lamartina L; Paciaroni A; Massa M; Giacomelli L; Ronga G; Filetti S;
J Clin Endocrinol Metab; 2012 Aug; 97(8):2748-53. PubMed ID: 22679061
[TBL] [Abstract][Full Text] [Related]
55. Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma.
Tamilia M; Al-Kahtani N; Rochon L; Hier MP; Payne RJ; Holcroft CA; Black MJ
Nucl Med Commun; 2011 Mar; 32(3):212-20. PubMed ID: 21191314
[TBL] [Abstract][Full Text] [Related]
56. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone.
Berg G; Lindstedt G; Suurküla M; Jansson S
J Endocrinol Invest; 2002 Jan; 25(1):44-52. PubMed ID: 11883865
[TBL] [Abstract][Full Text] [Related]
57. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
[TBL] [Abstract][Full Text] [Related]
58. I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence.
Shengguang Y; Ji-Eun C; Lijuan HL
Med Sci Monit; 2016 Jul; 22():2439-50. PubMed ID: 27406262
[TBL] [Abstract][Full Text] [Related]
59. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
60. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
